A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

This Phase 3 study tests whether adding a new drug called SHR-A1912 to a standard chemotherapy regimen (R-GemOx) improves outcomes for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or is not responding to treatment. **You may be eligible if...** - You are 18 to 79 years old - You have been diagnosed with DLBCL confirmed by a tissue sample - You have received at least one prior course of cancer treatment - You have at least one measurable tumor - You are in reasonably good health with a life expectancy of at least 3 months **You may NOT be eligible if...** - Your lymphoma involves the central nervous system (brain or spinal cord) - You have a specific subtype called primary mediastinal large B-cell lymphoma - You have a history of immunodeficiency - You have had another type of cancer in the past 5 years - You have serious heart disease Talk to your doctor to see if this trial is right for you.